Phaseline

Companies › Windward Bio

Windward Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Respiratory; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WIN378
TSLP ligand-blocking monoclonal antibody
TSLPPhase 2COPD (Chronic Obstructive Pulmonary Disease); AsthmaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07646587WIN378Phase 2COPD (Chronic Obstructive Pulmonary Disease)RespiratoryDec 2027
NCT07120503WIN378Phase 2AsthmaRespiratoryOct 2028

Targets

TSLP (1)

Companies with the same targets

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Suzhou Suncadia Biopharmaceuticals AstraZeneca Shanghai Huaota Biopharmaceutical

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.